The Leukemia Research Group (LRG)

Hilde Kollsete Gjelberg (MD)

Akutt myelogen leukemi (AML) er en aggressiv form for blodkreft, der umodne blodceller, kjent som myeloblaster, deler seg ukontrollert i benmargen. Til tross for fremskritt innen behandlingsstrategier, er prognosen fortsatt dårlig, med høy tilbakefallsrate og begrensede behandlingsmuligheter.

Integriner, som er overflatemolekyler involvert i celleadhesjon og signalering, spiller en nøkkelrolle i kreftcellers vekst, utvikling og resistens mot behandling. I dette prosjektet ønsker vi å undersøke betydningen av integriner og integrin-adhesjonskomplekset i sammenheng med AML. Målet er å identifisere spesifikke integrin-bioprofiler i AML ved hjelp av in vitro-studier av leukemiceller. Vi vil analysere hvordan disse profilene varierer mellom ulike AML-undertyper, hvilken rolle de spiller i interaksjonen mellom leukemiceller og stromale celler, samt vurdere deres potensial som mål for nye behandlingsstrategier.

Silje Johansen (MD)

Allogenic hematopoietic stem cell transplantation (allo-HSCT) is a well- established treatment towards malignant blood diseases. The treatment is extensive and associated with a high risk of transplantation related mortality and morbidity, with one of the main causes being graft versus host disease (GvHD). GvHD is when the immune cells from the donor lead to an immune- mediated patient organ damage. Our project’s main goal is to map the different mediator molecules and profiles of these molecules in association with development, prognosis and follow up of allo-HSCT patients, regarding GvHD. The project is funded by Helse Vest.

Marte Karen Lindstad Brattås (MD)

Acute myeloid leukemia (AML) is an aggressive hematological malignancy characterized by high mortality. Standard therapy is poorly tolerated even by young patients. The regulatory protein splenic tyrosine kinase (SYK) is recognized to be a potential target for the treatment of hematologic cancers. We want to explore SYK as a potential pharmacological target in acute myeloid leukemia. The project aims to characterize the heterogenicity of AML-patients based on in-vitro studies with regard to SYK-signaling and inhibition of SYK. The project is funded by Helse-Vest.

Anette Lodvir Hemsing (MD)

Main objective: explore the role of Ras-related C3 botulinum toxin substrate 1 (RAC1) in human acute myeloid leukemia cells, cultivated in standardized in vitro-models. Conduct a broad mapping of the biological profiles of RAC1 expression and signaling in AML patients, reflecting patient heterogeneity. Investigate the effect of RAC1 inhibition. Strengthen the fundament for future studies. 

Kimberley Hatfield (PhD):

Investigates metabolic phenotypes of primary human AML cells, and how metabolic pathways may be implicated in development of drug resistance in AML.

Additional research interests include the role of the microenvironment; in particular how AML cells are influenced by stromal cells and chemokines, and how leukemia cells adapt to changes in oxygen levels and nutrient availability.

Håkon Reikvam (Professor, MD, PhD):

Acute myelogenous leukemia (AML) is a highly malignant disease in which, despite advances in both pharmacological and cellular therapy, treatment outcomes remain suboptimal. Untreated, the disease is fatal in a very short time, i.e. weeks to months, and the total 5-year survival even for younger AML patients (<65 years) is still only approximately 40%. The main focus of our research projects is based on investigating new pharmacological treatment alternatives, as well as on studying conditions related to existing treatment, namely allogeneic stem cell transplantation (allo-SCT). Ongoing project agrees to investigate pharmacological intervention for three biological systems; (i) integrins, (ii) the SYK signaling pathway and (iii) the RAC1 signaling pathway. The basis for our project is several decades of collecting and biobanking of cell- and serum samples from patients treated at Haukeland University Hospital. The cells are cultured under standardized in vitro conditions, and well-described and developed methods will be used to study cell growth, cell death and changes in intracellular signaling mechanisms. Using serum samples, we have the opportunity to study changes in biological profiles for proteins, metabolites and other micromolecules, as well as search for potential biomarkers. The long-term possibilities for the project lie in the potential to implement research results for improvement and optimization of treatment for patients with AML in the health service.

Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!

Gjelberg HK, Helgeland L, Tsykunova G, Reikvam H.Expert Rev Hematol. 2024 Sep;17(9):543-546. doi: 10.1080/17474086.2024.2383395. Epub 2024 Jul 27.PMID: 39037042 

Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia.

Reikvam H, Dillon R.Expert Rev Hematol. 2024 Apr-May;17(4-5):103-106. doi: 10.1080/17474086.2024.2347303. Epub 2024 May 3.PMID: 38654593

 Monocytic Differentiation in Acute Myeloid Leukemia Cells: Diagnostic Criteria, Biological Heterogeneity, Mitochondrial Metabolism, Resistance to and Induction by Targeted Therapies.

Bruserud Ø, Selheim F, Hernandez-Valladares M, Reikvam H.Int J Mol Sci. 2024 Jun 8;25(12):6356. doi: 10.3390/ijms25126356.PMID: 38928061 

Preclinical activity of resazurin in acute myeloid leukaemia.

Ha TQ, Andresen V, Erikstein BS, Popa M, Gullaksen SE, Reikvam H, McCormack E, Gjertsen BT.Br J Haematol. 2024 Nov 24. doi: 10.1111/bjh.19872. Online ahead of print.PMID: 39582120

Clinical and imaging characteristics of patients with cardiac amyloidosis- a single center observational study.

Ingebrigtsen A, Saeed S, Larsen TH, Reikvam H.Scand J Clin Lab Invest. 2024 May;84(3):193-201. doi: 10.1080/00365513.2024.2346908. Epub 2024 May 6.PMID: 38709651

Low Incidence of Anti-PF4/Heparin Antibodies in Patients with Acute Myelogenous Leukemia.

Sørvoll IH, Lægreid IJ, Sollid T, Ahlen MT, Johansen S, Reikvam H.Mediterr J Hematol Infect Dis. 2024 Jul 1;16(1):e2024057. doi: 10.4084/MJHID.2024.057. eCollection 2024.PMID: 38984091 

 The Rac1-inhibitor EHop-016 attenuates AML cell migration and enhances the efficacy of daunorubicin in MOLM-13 transplanted zebrafish larvae.

Hemsing AL, Førde JL, Reikvam H, Herfindal L.Transl Oncol. 2024 Feb;40:101876. doi: 10.1016/j.tranon.2024.101876. Epub 2024 Jan 6.PMID: 38185059 

 Monocytic Differentiation of Human Acute Myeloid Leukemia Cells: A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations.

Selheim F, Aasebø E, Reikvam H, Bruserud Ø, Hernandez-Valladares M.Int J Mol Sci. 2024 May 7;25(10):5080. doi: 10.3390/ijms25105080.PMID: 38791118 

 Mass cytometric single cell immune profiles of peripheral blood from acute myeloid leukemia patients in complete remission with measurable residual disease.

Sefland Ø, Gullaksen SE, Omsland M, Reikvam H, Galteland E, Tran HTT, Spetalen S, Singh SK, Van Zeeburg HJT, Van De Loosdrecht AA, Gjertsen BT.Cytometry B Clin Cytom. 2024 Nov;106(6):485-496. doi: 10.1002/cyto.b.22197. Epub 2024 Jul 30.PMID: 39078053

A woman in her thirties with dyspnoea two weeks after abdominoplasty.

Saeed N, Taule EM, Vetti N, Saeed S, Leirgul E, Reikvam H.Tidsskr Nor Laegeforen. 2024 May 16;144(7). doi: 10.4045/tidsskr.23.0742. Print 2024 Jun 4

Patients with Bacterial Sepsis Are Heterogeneous with Regard to Their Systemic Lipidomic Profiles.

Mosevoll KA, Hansen BA, Gundersen IM, Reikvam H, Bruserud Ø, Bruserud Ø, Wendelbo Ø.Metabolites. 2022 Dec 29;13(1):52. doi: 10.3390/metabo13010052.PMID: 36676977

Platelets for advanced drug delivery in cancer.

Cacic D, Hervig T, Reikvam H.Expert Opin Drug Deliv. 2023 May;20(5):673-688. doi: 10.1080/17425247.2023.2217378. Epub 2023 May 26.PMID: 37212640 Review.

Better and safer allogeneic stem cell transplantation.

Reikvam H.Tidsskr Nor Laegeforen. 2023 Mar 13;143(4). doi: 10.4045/tidsskr.23.0083. Print 2023 Mar 14.PMID: 36919289

Tuberculosis-Associated Hemophagocytic Lymphohistiocytosis: A Review of Current Literature.

Fauchald T, Blomberg B, Reikvam H.J Clin Med. 2023 Aug 18;12(16):5366. doi: 10.3390/jcm12165366.PMID: 37629407 

Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia.

Reikvam H.Expert Rev Hematol. 2023 May;16(5):317-323. doi: 10.1080/17474086.2023.2202849. Epub 2023 Apr 17.PMID: 37066885

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia.

Bruserud Ø, Reikvam H.Cancers (Basel). 2023 Jul 21;15(14):3711. doi: 10.3390/cancers15143711.PMID: 37509370 

The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients.

Bruserud Ø, Mosevoll KA, Bruserud Ø, Reikvam H, Wendelbo Ø.Cells. 2023 Mar 24;12(7):1003. doi: 10.3390/cells12071003.PMID: 37048076 

VEXAS Syndrome in a Patient with Myeloproliferative Neoplasia.

Austestad J, Madland TM, Sandnes M, Haslerud TM, Benneche A, Reikvam H.Case Rep Hematol. 2023 Feb 25;2023:6551544. doi: 10.1155/2023/6551544. eCollection 2023.PMID: 36879894

Safety of hypoxic red blood cell administration in patients with transfusion-dependent hematological malignancies: An interim analysis.

Reikvam H, Hetland G, Ezligini F, Dorsch K, Omert L, Dunham A, Almeland SK.Transfus Apher Sci. 2023 Jun 22:103755. doi: 10.1016/j.transci.2023.103755. Online ahead of print.PMID: 37423867

Treatment and Response Evaluation Challenges in a Pregnant Woman With B-Cell Lymphoblastic Leukemia and Li-Fraumeni Syndrome.

Erikstein BS, Ahmed AB, Forthun RB, Leh F, Gjertsen BT, Reikvam H.J Hematol. 2023 Apr;12(2):92-99. doi: 10.14740/jh1107. Epub 2023 Apr 30.PMID: 37187497

 GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2.

Lellahi SM, Azeem W, Hua Y, Gabriel B, Paulsen Rye K, Reikvam H, Kalland KH.Front Immunol. 2023 Jan 12;13:1058963. doi: 10.3389/fimmu.2022.1058963. eCollection 2022.PMID: 36713392

Pretransplant systemic metabolic profiles in allogeneic hematopoietic stem cell transplant recipients - identification of patient subsets with increased transplant-related mortality.

Reikvam H, Bruserud Ø, Hatfield KJ.Transplant Cell Ther. 2023 Jun;29(6):375.e1-375.e14. doi: 10.1016/j.jtct.2023.03.020. Epub 2023 Mar 24.PMID: 36966869

Systemic Metabolomic Profiles in Adult Patients with Bacterial Sepsis: Characterization of Patient Heterogeneity at the Time of Diagnosis.

Mosevoll KA, Hansen BA, Gundersen IM, Reikvam H, Bruserud Ø, Bruserud Ø, Wendelbo Ø.Biomolecules. 2023 Jan 24;13(2):223. doi: 10.3390/biom13020223.PMID: 36830594 

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.

Lilleskare S, Vorland M, Vo AK, Aarsand AK, Reikvam H.Scand J Clin Lab Invest. 2023 Feb;83(1):3-7. doi: 10.1080/00365513.2022.2150984. Epub 2022 Dec 7.PMID: 36476017

En mann i 40-årene med transfusjonskrevende anemi.

Sandnes M, Helgeland L, Johansen S, Reikvam H.Tidsskr Nor Laegeforen. 2023 Oct 23;143(15). doi: 10.4045/tidsskr.23.0022. Print 2023 Oct 24.PMID: 37874056

Liposomal drug formulations for treatment of hematological malignancies.

Limi DC, Reikvam H.Expert Opin Pharmacother. 2023 Oct 12:1-4. doi: 10.1080/14656566.2023.2269086. Online ahead of print.PMID: 37823599 

Platelets for advanced drug delivery in cancer.

Cacic D, Hervig T, Reikvam H.Expert Opin Drug Deliv. 2023 May;20(5):673-688. doi: 10.1080/17425247.2023.2217378. Epub 2023 May 26.PMID: 37212640 

Iron Status and Physical Performance in Athletes.

Solberg A, Reikvam H.Life (Basel). 2023 Oct 2;13(10):2007. doi: 10.3390/life13102007.PMID: 37895389

Long-Smoldering T-prolymphocytic Leukemia: A Case Report and a Review of the Literature.

Gjelberg HK, Helgeland L, Liseth K, Micci F, Sandnes M, Russnes HG, Reikvam H.Curr Oncol. 2023 Nov 18;30(11):10007-10018. doi: 10.3390/curroncol30110727.PMID: 37999147 

Vacuolar ATPase Is a Possible Therapeutic Target in Acute Myeloid Leukemia: Focus on Patient Heterogeneity and Treatment Toxicity.

Bartaula-Brevik S, Leitch C, Hernandez-Valladares M, Aasebø E, Berven FS, Selheim F, Brenner AK, Rye KP, Hagen M, Reikvam H, McCormack E, Bruserud Ø, Tvedt THA.J Clin Med. 2023 Aug 25;12(17):5546. doi: 10.3390/jcm12175546.PMID: 37685612

PB1789: RAC1 INHIBITION IS FEASIBLE AND AFFECTS CELL MIGRATION IN A ZEBRAFISH LARVAE MODEL OF AML, INVESTIGATED USING A SOFTWARE TOOL FOR SINGLE-CELL VISUALIZATION

Anette Lodvir Hemsing, Jan-Lukas Førde, Kristin Paulsen Rye, Håkon Reikvam, Lars Herfindal

Hemasphere. 2023 Aug; 7(Suppl ): e9915813. Published online 2023 Aug 8. doi: 10.1097/01.HS9.0000974012.99158.13

PMCID: PMC10430263

5612976 FIRST ADMINISTRATION OF HYPOXIC BLOOD IN A TRANSFUSION-DEPENDENT PATIENT

H. Reikvam, G. Hetland, F. Ezligini, K. Dorsch, A. Dunham, L. Omert, S. Almeland

Hemasphere. 2023 Apr; 7(Suppl ): 41. Published online 2023 Apr 10. doi: 10.1097/01.HS9.0000928440.72522.5d

PMCID: PMC10112628

[Leukaemia cutis].

Holmemo HD, Reikvam H.Tidsskr Nor Laegeforen. 2021 Dec 22;141(1). doi: 10.4045/tidsskr.21.0695. Print 2022 Jan 11. PMID: 35026091

Eksamensformer i de norske medisinstudiene.

Raaheim OF, Raaheim DF, Reikvam H, Kvernenes M.Tidsskr Nor Laegeforen. 2022 Aug 12;142(11). doi: 10.4045/tidsskr.22.0337. Print 2022 Aug 16. PMID: 35997188

[When blood flows slowly].

Sandnes M, Reikvam H.Tidsskr Nor Laegeforen. 2022 Jun 7;142(9). doi: 10.4045/tidsskr.22.0026. Print 2022 Jun 14 PMID: 3569955

Lymphoplasmacytic variant of multiple myeloma.

Johansen S, Gjelberg HK, Reikvam H.EJHaem. 2022 Apr 8;3(2):563-564. doi: 10.1002/jha2.437. eCollection 2022 May PMID: 35846062

Thrombosis and thrombocytopenia after HPV vaccination.

Johansen S, Laegreid IJ, Ernstsen SL, Azrakhsh NA, Kittang AO, Lindås R, Gjertsen BT, Vetti N, Mørtberg TV, Sørvoll IH, Holme PA, Ahlen MT, Reikvam H.J Thromb Haemost. 2022 Mar;20(3):700-704. doi: 10.1111/jth.15604. Epub 2021 Dec 7. PMID: 34817130

Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia.

Reikvam H, Hemsing AL, Hernandez-Valladares M, Birkeland E.Expert Rev Proteomics. 2022 Feb;19(2):73-76. doi: 10.1080/14789450.2022.2067530. Epub 2022 Apr 22. PMID: 35436165

MicroRNA serum profiles and chronic graft-versus-host disease.

Reikvam H, Vo AK, Johansen S, Hemsing AL, Solheim MH, Mosevoll KA, Tvedt THA, Hatfield KJ.Blood Adv. 2022 Sep 27;6(18):5295-5306. doi: 10.1182/bloodadvances.2021005930. PMID: 35443023

Autologous hematopoietic stem cell grafts - moving away from a one-size-fits-all approach.

Melve GK, Sandnes M, Reikvam H.Expert Rev Hematol. 2022 Jan;15(1):1-4. doi: 10.1080/17474086.2022.2022470. Epub 2022 Jan 6. PMID: 34949139

Cytomegalovirus induced hemophagocytic lymphohistiocytosis: diagnostic and treatment challenges for the future.

Rolsdorph LÅ, Mosevoll KA, Reikvam H.Expert Rev Hematol. 2022 Aug;15(8):667-670. doi: 10.1080/17474086.2022.2100341. Epub 2022 Jul 17. PMID: 35819263

Human papilloma virus vaccine and VITT antibody induction.

Kanack AJ, Laegreid IJ, Johansen S, Reikvam H, Ahlen MT, Padmanabhan A.Am J Hematol. 2022 Oct;97(10):E363-E364. doi: 10.1002/ajh.26659. Epub 2022 Aug 3. PMID: 35834243

Pure red cell aplasia after hematopoietic stem cell transplantation - experimental therapeutic approaches.

Vo AK, Hervig T, Reikvam H.Expert Opin Investig Drugs. 2022 Sep;31(9):881-884. doi: 10.1080/13543784.2022.2113055. PMID: 35975626

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.

Reikvam H, Hatfield KJ, Wendelbo Ø, Lindås R, Lassalle P, Bruserud Ø.Biomolecules. 2022 Mar 24;12(4):492. doi: 10.3390/biom12040492.

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives.

Reikvam H, Hatfield KJ, Wendelbo Ø, Lindås R, Lassalle P, Bruserud Ø.Biomolecules. 2022 Mar 24;12(4):492. doi: 10.3390/biom12040492. PMID: 35454082

Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis.

Thunestvedt LMØ, Helgeland L, Bachmann IM, Karlsdottir Å, Haslerud TM, Reikvam H.Curr Oncol. 2022 Mar 23;29(4):2193-2198. doi: 10.3390/curroncol29040178. PMID: 35448152

Limbic Encephalitis following Allogeneic Hematopoietic Stem Cell Transplantation.

Johansen S, Kråkenes J, Vedeler CA, Storstein AM, Reikvam H.Case Reports Immunol. 2022 Sep 10;2022:4174755. doi: 10.1155/2022/4174755. eCollection 2022 PMID: 36124252

NPM1-Mutated Patient-Derived AML Cells Are More Vulnerable to Rac1 Inhibition.

Hemsing AL, Rye KP, Hatfield KJ, Reikvam H.Biomedicines. 2022 Aug 4;10(8):1881. doi: 10.3390/biomedicines10081881. PMID: 36009428

Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients.

Hatfield KJ, Bruserud Ø, Reikvam H.Cancers (Basel). 2022 Jun 13;14(12):2910. doi: 10.3390/cancers14122910. PMID: 35740576

Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia.

Bruserud Ø, Reikvam H, Brenner AK.Molecules. 2022 Jan 23;27(3):735. doi: 10.3390/molecules27030735. PMID: 35163998

Concomitant Hemophagocytic Lymphohistiocytosis and Cytomegalovirus Disease: A Case Based Systemic Review.

Rolsdorph LÅ, Mosevoll KA, Helgeland L, Reikvam H.Front Med (Lausanne). 2022 Apr 19;9:819465. doi: 10.3389/fmed.2022.819465. eCollection 2022. PMID: 35514747

Musculoskeletal Chronic Graft versus Host Disease-A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature.

Kvinge AD, Kvammen T, Miletic H, Bindoff LA, Reikvam H.Curr Oncol. 2022 Nov 3;29(11):8415-8430. doi: 10.3390/curroncol29110663. PMID: 36354723

Weight gain during treatment course of allogenic hematopoietic stem cell transplantation in patients with hematological malignancies affects treatment outcome.

Johansen S, Blomberg B, Vo AK, Wendelbo Ø, Reikvam H.Cytotherapy. 2022 Dec;24(12):1190-1194. doi: 10.1016/j.jcyt.2022.08.006. Epub 2022 Sep 20. PMID: 36151003

An Abrupt Transition to Digital Teaching-Norwegian Medical Students and Their Experiences of Learning Output during the Initial Phase of the COVID-19 Lockdown.

Helland HK, Tylleskär T, Kvernenes M, Reikvam H.Healthcare (Basel). 2022 Jan 17;10(1):170. doi: 10.3390/healthcare10010170. PMID: 35052333

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.

Lilleskare S, Vorland M, Vo AK, Aarsand AK, Reikvam H.Scand J Clin Lab Invest. 2022 Dec 7:1-5. doi: 10.1080/00365513.2022.2150984. Online ahead of print.PMID: 36476017

Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition.

Brattås MK, Hemsing AL, Rye KP, Hatfield KJ, Reikvam H.Int J Mol Sci. 2022 Nov 25;23(23):14706. doi: 10.3390/ijms232314706.PMID: 36499034 

Ekstrem hypertriglyseridemi.

Vinnes EW, Hemsing AL.Tidsskr Nor Laegeforen. 2022 Nov 7;142(16). doi: 10.4045/tidsskr.22.0546. Print 2022 Nov 8.PMID: 36345642 

Thrombocytopaenia in the critically ill.

Bruserud Ø, Mosevoll KA, Kristoffersen E, Kvåle R, Reikvam H.Tidsskr Nor Laegeforen. 2021 Jan 11

Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach.

Reikvam H, Hemsing AL, Smith C.Expert Rev Anticancer Ther. 2021 Jan;21

Hyperferritinemia-A Clinical Overview.

Sandnes M, Ulvik RJ, Vorland M, Reikvam H.J Clin Med. 2021 May 7

Thrombosis and thrombocytopenia after HPV vaccination.

Johansen S, Laegreid IJ, Ernstsen SL, Azrakhsh NA, Kittang AO, Lindås R, Gjertsen BT, Vetti N, Mørtberg TV, Sørvoll IH, Holme PA, Ahlen MT, Reikvam H.J Thromb Haemost. 2021 Nov 24

Immunoglobulin-Storing Histiocytosis: A Case Based Systemic Review.

Wiese-Hansen H, Leh F, Lodvir Hemsing A, Reikvam H.J Clin Med. 2021 Apr

[A young woman with dyspnoea and proteinuria].

Hervig T, Tvedt THA, Knoop T, Sandnes M, Reikvam H.Tidsskr Nor Laegeforen. 2021 Nov  

Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences.

Tvedt THA, Vo AK, Bruserud Ø, Reikvam H.J Clin Med. 2021 Nov 6

Carbapenem-Resistant Enterobacteriaceae-Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies.

Storhaug KØ, Skutlaberg DH, Hansen BA, Reikvam H, Wendelbo Ø.Antibiotics (Basel). 2021 Mar 19

Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis.

Bruserud Ø, Tvedt THA, Ahmed AB, Vintermyr OK, Hervig T, Guttormsen AB, Reikvam H.Case Rep Crit Care. 2021 Mar 8

Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia-Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation.

Bruserud Ø, Tsykunova G, Hernandez-Valladares M, Reikvam H, Tvedt THA.Pharmaceuticals (Basel). 2021 May 2

Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis.

Cacic D, Reikvam H, Nordgård O, Meyer P, Hervig T.Cancers (Basel). 2021 Apr 14

Kidney Failure and Abdominal Discomfort as Initial Signs of Extramedullary Acute Myelogenous Leukemia.

Steinfeld PF, Knoop T, Trovik LH, Gjelberg HK, Haslerud TM, Reikvam H.Clin Pract. 2021 Jul 22

HFE Genotype, Ferritin Levels and Transferrin Saturation in Patients with Suspected Hereditary Hemochromatosis.

Sandnes M, Vorland M, Ulvik RJ, Reikvam H.Genes (Basel). 2021 Jul 28

Future perspective: metabolism as a therapeutic target in acute myeloid leukemia - from Warburg to precision medicine.

Hatfield KJ, Grønningsaeter IS, Reikvam H.Curr Med Res Opin. 2021 Dec

Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity.

Grønningsæter IS, Reikvam H, Aasebø E, Bartaula-Brevik S, Hernandez-Valladares M, Selheim F, Berven FS, Tvedt TH, Bruserud Ø, Hatfield KJ.J Pers Med. 2021 Aug

Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells.

Aasebø E, Brenner AK, Hernandez-Valladares M, Birkeland E, Mjaavatten O, Reikvam H, Selheim F, Berven FS, Bruserud Ø.Diseases. 2021 Oct 16

Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid.

Hernandez-Valladares M, Wangen R, Aasebø E, Reikvam H, Berven FS, Selheim F, Bruserud Ø.Cancers (Basel). 2021 Apr 29

p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy.

Haaland I, Hjelle SM, Reikvam H, Sulen A, Ryningen A, McCormack E, Bruserud Ø, Gjertsen BT.Cells. 2021 Apr 7

Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation.

Hemsing AL, Gjertsen BT, Spetalen S, Helgeland L, Reikvam H.SAGE Open Med Case Rep. 2021 Jan 22

  Future perspective: precision medicine to improve treatment results in the settings of allogenic stem cell transplantation for acute myelogenous leukemia, Reikvam H, Johansen S, Koenecke C. Expert Review of Precision Medicine and Drug Development March 2021 6(2):1-5

Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation.   Reikvam H, Tvedt THA, Johansen, S, Aase Setran H, Havre RF. Transplantology 2020, 1, 102-110.

The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles.

Aasebø E, Berven FS, Hovland R, Døskeland SO, Bruserud Ø, Selheim F, Hernandez-Valladares M. Cancers (Basel). 2020 Jun 4;12(6):1466. doi: 10.3390/cancers12061466.

The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.

Nepstad I, Hatfield KJ, Grønningsæter IS, Reikvam H. Int J Mol Sci. 2020 Apr 21;21(8):2907. doi: 10.3390/ijms21082907.

 Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia.

Aasebø E, Berven FS, Bartaula-Brevik S, Stokowy T, Hovland R, Vaudel M, Døskeland SO, McCormack E, Batth TS, Olsen JV, Bruserud Ø, Selheim F, Hernandez-Valladares M. Cancers (Basel). 2020 Mar 17;12(3):709. doi: 10.3390/cancers12030709.

The Systemic Metabolic Profile Early after Allogeneic Stem Cell Transplantation: Effects of Adequate Energy Support Administered through Enteral Feeding Tube.

Tvedt THA, Skaarud KJ, Tjønnfjord GE, Gedde-Dahl T, Iversen PO, Bruserud Ø. Biol Blood Marrow Transplant. 2020 Feb;26(2):380-391. doi: 10.1016/j.bbmt.2019.10.005. Epub 2019 Oct 14.

 Immunomodulatory Drugs Alter the Metabolism and the Extracellular Release of Soluble Mediators by Normal Monocytes.

Rundgren IM, Ryningen A, Anderson Tvedt TH, Bruserud Ø, Ersvær E. Molecules. 2020 Jan 16;25(2):367. doi: 10.3390/molecules25020367.

Febrile Neutropenia in Acute Leukemia. Epidemiology, Etiology, Pathophysiology and Treatment.

Hansen BA, Wendelbo Ø, Bruserud Ø, Hemsing AL, Mosevoll KA, Reikvam H. Mediterr J Hematol Infect Dis. 2020 Jan 1;12(1):e2020009. doi: 10.4084/MJHID.2020.009. eCollection 2020.

Probiotics to manage inflammation in HIV infection.

Reikvam DH, Meyer-Myklestad MH, Trøseid M, Stiksrud B. Curr Opin Infect Dis. 2020 Feb;33(1):34-43. doi: 10.1097/QCO.0000000000000612.

Hyperferritinemi-katarakt-syndrom.

Benneche A, Sandnes M, Bakke Å, Reikvam H. Tidsskr Nor Laegeforen. 2020 Nov 9;140(16). doi: 10.4045/tidsskr.20.0255. Print 2020 Nov 10.

Targeting Cellular Metabolism in Acute Myeloid Leukemia and The Role of Patient Heterogeneity.

Grønningsæter IS, Reikvam H, Aasebø E, Bartaula-Brevik S, Tvedt TH, Bruserud Ø, Hatfield KJ. Cells. 2020 May 7;9(5):1155. doi: 10.3390/cells9051155.

Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach.

Reikvam H, Hemsing AL, Smith C. Expert Rev Anticancer Ther. 2020 Oct 25:1-4. doi: 10.1080/14737140.2021.1838901.

COVID-19 and venous thromboembolism - prophylaxis and treatment.

Kvåle R, Azrakhsh NA, Mohn KG, Aanerud M, Guttormsen AB, Reikvam H. Tidsskr Nor Laegeforen. 2020 Jun 17;140(11). doi: 10.4045/tidsskr.20.0440.

Inhibition of NF-κB Signaling Alters Acute Myelogenous Leukemia Cell Transcriptomics.

Reikvam H. Cells. 2020 Jul 12;9(7):1677. doi: 10.3390/cells9071677.

Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report.

Trovik LH, Sandnes M, Blomberg B, Holmaas G, Ahmed AB, Tvedt THA, Vintermyr O, Reikvam H. J Med Case Rep. 2020 Nov 11;14(1):217. doi: 10.1186/s13256-020-02555-x.

Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder.

Bruserud Ø, Wendelbo Ø, Vetti N, Goplen FK, Johansen S, Reikvam H. Clin Pract. 2020 Jun 10;10(2):1214. doi: 10.4081/cp.2020.1214. eCollection 2020 May 19.

Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment.

Vo AK, Kollsete Gjelberg H, Hovland R, Lindstad Brattås MK, Bruserud Ø, Reikvam H. Case Rep Hematol. 2020 Jan 20;2020:1262038. doi: 10.1155/2020/1262038. eCollection 2020.

Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy.

Vo AK, Reikvam H, Midtbø H, Wirsching JL, Bruserud Ø, Wendelbo Ø. Case Rep Anesthesiol. 2020 Oct 15;2020:4219616. doi: 10.1155/2020/4219616. eCollection 2020.

Epiglottitt.

Bruserud Ø, Engesæter IØ, Mjelle KE, Kristensen F, Wendelbo Ø. Tidsskr Nor Laegeforen. 2020 Sep 11;140(13). doi: 10.4045/tidsskr.20.0382. Print 2020 Sep 29.

The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives.

Hernandez-Valladares M, Bruserud Ø, Selheim F. Int J Mol Sci. 2020 Sep 17;21(18):6830. doi: 10.3390/ijms21186830.

Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer-What Can We Learn from the Hematological Experience?

Bruserud Ø, Aarstad HH, Tvedt THA. Cancers (Basel). 2020 Jul 19;12(7):1966. doi: 10.3390/cancers12071966.

Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder.

Bruserud Ø, Wendelbo Ø, Vetti N, Goplen FK, Johansen S, Reikvam H. Clin Pract. 2020 Jun 10;10(2):1214. doi: 10.4081/cp.2020.1214. eCollection 2020 May 19.

Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC).

Gudbrandsdottir G, Aarstad HH, Bostad L, Hjelle KM, Aarstad HJ, Bruserud Ø, Tvedt THA, Beisland C. Cancer Immunol Immunother. 2020 Jul 3. doi: 10.1007/s00262-020-02655-z. Online ahead of print

A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies.

Rundgren IM, Ersvær E, Ahmed AB, Ryningen A, Bruserud Ø. Medicina (Kaunas). 2020 Jan 18;56(1):36. doi: 10.3390/medicina56010036.

The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile.

Aarstad HH, Guðbrandsdottir G, Hjelle KM, Bostad L, Bruserud Ø, Tvedt THA, Beisland C. Cancers (Basel). 2020 Jul 19;12(7):1961. doi: 10.3390/cancers12071961.

The Acute Phase Reaction and Its Prognostic Impact in Patients with Head and Neck Squamous Cell Carcinoma: Single Biomarkers Including C-Reactive Protein Versus Biomarker Profiles.

Aarstad HH, Moe SEE, Bruserud Ø, Lybak S, Aarstad HJ, Tvedt THA. Biomedicines. 2020 Oct 14;8(10):418. doi: 10.3390/biomedicines8100418.

Intermediate-High Risk Pulmonary Embolism: The Use of Riociguat and Inferior Vena Cava Filter in a Situation of Recurrent Embolism following Insufficient Anticoagulation and Fibrinolytic Therapy.

Vo AK, Reikvam H, Midtbø H, Wirsching JL, Bruserud Ø, Wendelbo Ø. Case Rep Anesthesiol. 2020 Oct 15;2020:4219616. doi: 10.1155/2020/4219616. eCollection 2020.

Cold agglutinin disease revisited: a multinational, observational study of 232 patients.

Berentsen S, Barcellini W, D'Sa S, Randen U, Tvedt THA, Fattizzo B, Haukås E, Kell M, Brudevold R, Dahm AEA, Dalgaard J, Frøen H, Hallstensen RF, Jæger PH, Hjorth-Hansen H, Małecka A, Oksman M, Rolke J, Sekhar M, Sørbø JH, Tjønnfjord E, Tsykunova G, Tjønnfjord GE. Blood. 2020 Jul 23;136(4):480-488. doi: 10.1182/blood.2020005674.

Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.

Michel M, Ruggeri M, Gonzalez-Lopez TJ, Alkindi SS, Cheze S, Ghanima W, Tvedt THA, Ebbo M, Terriou L, Bussel JB, Godeau B. Blood. 2020 Aug 19:blood.2020007594. doi: 10.1182/blood.2020007594.